sEHI + Undisclosed 2

sEHI + Undisclosed 2 is an experimental combination therapy consisting of a soluble epoxide hydrolase inhibitor (sEHI) and a second, undisclosed agent. Soluble epoxide hydrolase inhibitors are small molecules that block the activity of the soluble epoxide hydrolase enzyme, which is involved in the metabolism of bioactive lipid mediators such as epoxyeicosatrienoic acids (EETs). Inhibition of this enzyme increases EET levels, which can have anti-inflammatory, analgesic, and cardiovascular protective effects. The identity and mechanism of action for "Undisclosed 2" are not publicly available. This combination is under investigation for potential therapeutic applications.